Iruplinalkib
- Generic Name
- Iruplinalkib
- Drug Type
- Small Molecule
- CAS Number
- 1854943-32-0
- Unique Ingredient Identifier
- Z5F65W1YAZ
- Indication
用于既往接受过克唑替尼治疗后疾病进展或对克唑替尼不耐受的间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的治疗。
Iruplinalkib Shows Sustained Benefit in Crizotinib-Resistant NSCLC
• Updated data from the Phase II INTELLECT study reveals that iruplinalkib demonstrates a median overall survival of 41.79 months in NSCLC patients.
• The study reported an objective response rate of 63.7% and a disease control rate of 94.5% with iruplinalkib in crizotinib-resistant NSCLC.
• Iruplinalkib showed promising intracranial activity in patients with CNS metastasis, with an intracranial objective response rate of 64.3%.
• The safety profile of iruplinalkib remains consistent, with no new safety signals identified in the extended follow-up.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath